Previous Article | Back To List | Next Article

Medac Pharma, Inc. Announces Settlement of Patent Infringement Lawsuits

Medac Pharma, Inc. announced today that it and its parent company, medac GmbH, have settled all litigation and patent office proceedings with Antares Pharma, Inc.

Chicago, IL, April 16, 2015

Medac Pharma, Inc., a privately-held pharmaceutical company, today announced that it and its parent company, medac GmbH, have settled all litigation and patent office proceedings with Antares Pharma, Inc. Pursuant to the settlement agreement, the parties will dismiss proceedings related to their respective patents pending before the United States District Court for the District of Delaware, the United States District Court for the District of New Jersey, the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office, and the Technical Board of Appeal of the European Patent Office. The settlement agreement also provides for a royalty-free cross-license under the patents-in-suit and their families allowing the manufacture and sale of Medac’s RASUVO™ and Antares’ OTREXUP™ in and for the U.S.

About Medac Pharma: Practicing a patient-first philosophy

Medac Pharma, Inc. is a privately held specialty pharmaceutical company focused on the development, in-licensing and commercialization of late-stage molecules. The company strives to bring new life to products and solve everyday patient challenges in autoimmune disease and cancer.

Medac Pharma is the wholly-owned subsidiary of medac GmbH, a well known and respected global pharmaceutical company that has been making scientific and therapeutic discoveries for more than 40 years. For more information about medac GmbH, please visit www.medac.de.

For complete prescribing information, including Boxed Warning, and information on Medac Pharma’s CORE Connections program, please visit www.Rasuvo.com.

For Media:
Tiberend Strategic Advisors, Inc.
Andrew Mielach
amielach@tiberend.com; (212) 375-2694